These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24784785)

  • 21. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids.
    Manchikanti L; Singh A
    Pain Physician; 2008 Mar; 11(2 Suppl):S63-88. PubMed ID: 18443641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic agents off the darknet: a case of U-47700 and phenazepam abuse.
    Vo KT; van Wijk XM; Wu AH; Lynch KL; Ho RY
    Clin Toxicol (Phila); 2017 Jan; 55(1):71-72. PubMed ID: 27736261
    [No Abstract]   [Full Text] [Related]  

  • 23. Urine drug screening: opioid risks preclude complete patient autonomy.
    Darnall BD; Schatman ME
    Pain Med; 2014 Dec; 15(12):2001-2. PubMed ID: 25376661
    [No Abstract]   [Full Text] [Related]  

  • 24. [Driving safety and pain therapy].
    Petzke F; Scharnagel R; Sabatowski R
    MMW Fortschr Med; 2015 Mar; 157 Suppl 1():80-2. PubMed ID: 26012994
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of random and postaccident urine drug tests in southern Indiana coal miners.
    Price JW
    J Addict Med; 2012 Dec; 6(4):253-7. PubMed ID: 22895464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urine drug testing for pain management.
    Magnani B; Kwong T
    Clin Lab Med; 2012 Sep; 32(3):379-90. PubMed ID: 22939297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients.
    Adams LL; Gatchel RJ; Robinson RC; Polatin P; Gajraj N; Deschner M; Noe C
    J Pain Symptom Manage; 2004 May; 27(5):440-59. PubMed ID: 15120773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Organizational, legal, and methodical aspects of drug abuse prevention].
    Novikov VA; Dorovskikh IV; Mal'tsev GIu; Likhachev AA; Kozlov AA
    Voen Med Zh; 2007 Apr; 328(4):62-7. PubMed ID: 17580495
    [No Abstract]   [Full Text] [Related]  

  • 29. Misuse of and dependence on opioids: study of chronic pain patients.
    Kahan M; Srivastava A; Wilson L; Gourlay D; Midmer D
    Can Fam Physician; 2006 Sep; 52(9):1081-7. PubMed ID: 17279218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Designer drugs--diagnostic, psychological and low aspects of problem].
    Morawska-Siudak J; Szkolnicka B; Gomółka E; Krawczyk-Pasławska E
    Przegl Lek; 2010; 67(8):598-601. PubMed ID: 21387785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pill counts and pill rental: unintended entrepreneurial opportunities.
    Viscomi CM; Covington M; Christenson C
    Clin J Pain; 2013 Jul; 29(7):623-4. PubMed ID: 23328335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid urine drug screens: diphenhydramine and methadone cross-reactivity.
    Rogers SC; Pruitt CW; Crouch DJ; Caravati EM
    Pediatr Emerg Care; 2010 Sep; 26(9):665-6. PubMed ID: 20838187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testing for drugs of abuse.
    Colyar MR
    Adv Nurse Pract; 2003 Sep; 11(9):30-1. PubMed ID: 14521106
    [No Abstract]   [Full Text] [Related]  

  • 35. Retrospective review of physician opioid prescribing practices in patients with aberrant behaviors.
    Gupta A; Patton C; Diskina D; Cheatle M
    Pain Physician; 2011; 14(4):383-9. PubMed ID: 21785482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of urine drug monitoring in chronic opioid therapy: an analysis of current clinician behavior.
    Clancy Z; O'Connell K; Couto J
    J Opioid Manag; 2013; 9(2):121-7. PubMed ID: 23709321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protocol for accuracy of point of care (POC) or in-office urine drug testing (immunoassay) in chronic pain patients: a prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS).
    Manchikanti L; Malla Y; Wargo BW; Cash KA; Pampati V; Damron KS; McManus CD; Brandon DE
    Pain Physician; 2010; 13(1):E1-E22. PubMed ID: 20119473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinalysis-based comparative evaluation of pattern of use of dextropropoxyphene and buprenorphine among opioid-dependent subjects.
    Balhara YP; Jain R
    J Opioid Manag; 2012; 8(1):45-9. PubMed ID: 22479884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Legal issues facing physicians: substance abuse in the workplace.
    Clark HW; Johnson B
    Occup Med; 2002; 17(1):119-35, v. PubMed ID: 11726341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of urine drug testing for patients on opioid therapy.
    Pergolizzi J; Pappagallo M; Stauffer J; Gharibo C; Fortner N; De Jesus MN; Brennan MJ; Richmond C; Hussey D;
    Pain Pract; 2010; 10(6):497-507. PubMed ID: 20412503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.